Stevanato Group (NYSE: STVN)
Stevanato Group (NYSE: STVN)
One-line summary: Q2 FY2026 revenue €302.0M +8%; HVS €135.9M +16% (45% of sales). FY guide narrowed to €1.260–€1.280B. GLP-1 22–23% of Q2 revenue is slides + Franco remarks, not 6-K highlights.
What it is
Italian glass container and drug delivery systems manufacturer. Makes prefilled syringes, glass vials, and cartridges for injectable drugs (primary containers), plus fill-finish CDMO services. Its Nexa prefilled syringes and EZ-fill cartridges are the highest-value products — specifically designed for GLP-1 biologics requiring specialized handling. NYSE-listed with US liquidity. NYSE: STVN confirmed on the Q2 clip.
Why it matters to stock-market
Every injectable GLP-1 dose needs a primary container. Novo Nordisk's acquisition of three Catalent fill-finish sites ($11B) removed those sites from the independent market — structurally redirecting Lilly and other GLP-1 developers toward Stevanato and Lonza. This is a multi-year structural demand lock created by Novo's captive strategy.
Valuation (August 27, 2026)
Last: $22.30 at the Thu 27 Aug 2026 4:00 PM EDT close. From 2026-08-28-wst-stvn-q2-fy2026-glp1-hardware.
Gage's judgment (as of 2026-08-27)
Gage, 27 Aug 2026, via Leo. ~25% up / ~25% down over 18–24 months. Gage's judgment, not grain / not issuer fact. Last-price as-of stays the vault last: $22.30 (Thu 27 Aug 2026 4:00 PM EDT). Better price, messier facts (guide narrow, Fishers end-2028, 22–23% slides+Franco). Not a buy/sell/size. Not a paper sleeve. No source URL — do not invent one.
Key facts
- Q2 FY2026 print (6-K EX-99.1 4 Aug): revenue €302.0M +8%. HVS €135.9M +16%, 45% of sales. Diluted EPS €0.08; adj €0.14. From 2026-08-28-wst-stvn-q2-fy2026-glp1-hardware.
- FY guide narrowed to €1.260–€1.280B. Balda sale €12.2M one-time; ~€30M FY revenue out. From 2026-08-28-wst-stvn-q2-fy2026-glp1-hardware.
- GLP-1 22–23% of Q2 revenue is slides + Franco remarks, not in the 6-K press-release highlights. Leave that label on the number. From 2026-08-28-wst-stvn-q2-fy2026-glp1-hardware.
- Fishers: first EZ-fill vial PQ done; full ramp end-2028. Latina RTU 400 commercial 2027. Demand “strong and robust.” From 2026-08-28-wst-stvn-q2-fy2026-glp1-hardware.
- Contested biologics split: slides “Biologics that grew 30% yoy” vs Franco Q&A “6% of growth in biologics.” Leave the split. Do not flatten. From 2026-08-28-wst-stvn-q2-fy2026-glp1-hardware.
- GLP-1 revenue 2025 (prior): Grew >50% vs 2024; GLP-1 = ~19-20% of total 2025 revenue. From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries.
- Nexa prefilled syringes (prior): Fastest-growing product, driven primarily by GLP-1. Customer base for high-value prefilled syringes grew >40% in 2025. From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries.
- 2026 guidance (prior, superseded at the top end): Full-year revenue €1.260–€1.290B; GLP-1 growth "mid-teens" percentage; high-value solutions ~47-48% of revenue. From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries. Q2 narrows the range to €1.260–€1.280B.
- CapEx (prior): €294.9M in 2025 (89% growth-directed); Fishers, Indiana plant targeting commercial activities end-2026 / early 2027. From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries. Q2 moves Fishers full ramp to end-2028 (first EZ-fill vial PQ done).
- Structural demand shift (prior): Novo Nordisk acquired Catalent's three fill-finish sites → captive to Novo. Eli Lilly CEO publicly complained this could damage competitors' access. Lilly redirects to STVN and Lonza. From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries.
- Injectable dominance (Q1-era prior, unfetched this pass): Management projects injectable GLP-1s will remain ~70% of total GLP-1 volume even as oral pills grow. From 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries. The Q1 70/30 injectable/oral-as-long-run-opportunity line was not re-fetched on this clip — leave open; do not treat as current TRx.
- Orals are a live derailer, not a printed mix collapse. Foundayo shipping (approved 1 Apr 2026 / ship 6 Apr). Wegovy pill 3M Rx since 5 Jan; >80% new-to-GLP-1. Class-level oral share >30% is not established. STVN GLP-1 mix is up, not down (22–23% slides+Franco). Injectable unit volumes still undisclosed. From 2026-08-28-wst-stvn-q2-fy2026-glp1-hardware.
- 503B still a proposal. 91 FR 23431 + comment extension to July 30 (FR-2026-12937 fetched). No final. Closing, not reopening. Same source.
- June honest gap stays open: pricing power vs normalized capacity still inferred. Same source.
Strengths
- Direct beneficiary of Novo's Catalent acquisition redirecting Lilly/other demand to independents
- NYSE-listed (liquid); Q2 reprints HVS at 45% of sales and +16%
- US Fishers plant: first EZ-fill vial PQ done; Latina RTU 400 commercial 2027
- Demand described as “strong and robust” on the IR transcript
Risks
- FY guide narrowed (top end €1.290B → €1.280B) with Balda ~€30M FY revenue out
- GLP-1 22–23% is slides + Franco, not 6-K highlights
- Biologics 30% yoy vs “6% of growth” is unresolved
- Oral GLP-1 risk is live (Foundayo shipping) but class share >30% is not established; 70/30 durability not re-fetched; mix is up; units undisclosed
- Concentrated customer risk: if Novo or Lilly brings fill-finish in-house beyond Catalent, STVN volumes could lag guidance
- One-customer variable compensation for missed committed volumes — unfetched; leave open
Open questions
- STVN one-customer variable compensation for missed committed volumes — unfetched primary.
- Q1 70/30 injectable/oral as long-run opportunity, not current TRx — unfetched this pass.
- Class-level oral share >30% — not established.
- June honest gap: pricing power vs normalized capacity — still inferred.
- Gage range is on this page as Gage's judgment (Gage, 27 Aug 2026, via Leo), not grain.
Sources
- 2026-08-28-wst-stvn-q2-fy2026-glp1-hardware — Q2 FY2026 6-K / IR slides / IR transcript; FY guide narrow; GLP-1 22–23% labeled slides+Franco; orals live / class share not established; 503B proposal + July 30 comment extension; Aug 27 close $22.30. Gage ranges are on this page as Gage's judgment, not grain (Gage, 27 Aug 2026, via Leo — not this clip; no source URL). Not a buy/sell/size. Encyclopedia not used.
- 2026-06-08-autoresearch-glp1-healthcare-supply-chain-beneficiaries